Gemcitabine and Nab-Paclitaxel Combination Therapy for the Treatment of Metastatic Pancreatic Cancer

Background: The superiority of gemcitabine and nab-paclitaxel combination therapy over gemcitabine alone in patients with metastatic pancreatic cancer has been demonstrated in MPACT trial. In December 2014, this combination therapy has been approved in Japan. The aim of this study is to clarify the treatment outcomes of this combination therapy in our clinical practice.Methods: Medical records were retrospectively reviewed for consecutive patients receiving gemcitabine and nab-paclitaxel combination therapy at out hospital between January 2015 and January 2016.Results: One hundred and sixty-seven patients were treated by gemcitabine and nab-paclitaxel combination therapy for the treatment of advanced pancreatic cancer in total. Among these patients, seventy patients with chemo-naïve metastatic pancreatic cancer were analyzed: median age of 67, male gender in 52.9%, performance status of 0 in 74.3%, cancers in the head of pancreas in 40.0%. Median follow-up period was 4.4 months. Response rate and disease control rate were 30.0% and 82.0%, respectively. Median progression-free survival and overall survival were 5.9 months and 10.4 months.Conclusion: Although the median follow-up period is still short, gemcitabine and nab-paclitaxel combination therapy shows good treatment efficacy for the treatment of metastatic pancreatic cancer. The updated data will be shown at the meeting. Background: The superiority of gemcitabine and nab-paclitaxel combination therapy over gemcitabine alone in patients with metastatic pancreatic cancer has been demonstrated in MPACT trial. In December 2014, this combination therapy has been approved in Japan. The aim of this study is to clarify the treatment outcomes of this combination therapy in our clinical practice. Methods: Medical records were retrospectively reviewed for consecutive patients receiving gemcitabine and nab-paclitaxel combination therapy at out hospital between January 2015 and January 2016. Results: One hundred and sixty-seven patients were treated by gemcitabine and nab-paclitaxel combination therapy for the treatment of advanced pancreatic cancer in total. Among these patients, seventy patients with chemo-naïve metastatic pancreatic cancer were analyzed: median age of 67, male gender in 52.9%, performance status of 0 in 74.3%, cancers in the head of pancreas in 40.0%. Median follow-up period was 4.4 months. Response rate and disease control rate were 30.0% and 82.0%, respectively. Median progression-free survival and overall survival were 5.9 months and 10.4 months. Conclusion: Although the median follow-up period is still short, gemcitabine and nab-paclitaxel combination therapy shows good treatment efficacy for the treatment of metastatic pancreatic cancer. The updated data will be shown at the meeting.